Topiramate, a new anticonvulsant, is also used for the prophylaxis of migraine and cluster headache. A serious but not often discussed side effect of the drug is the development of acute myopia and acute angle-closure glaucoma in the early stage of therapy that subsides rapidly with prompt discontinuation. One such case is reported here and the relevant literature in this regard is also reviewed.
Introduction
Topiramate is a broad-spectrum anticonvulsant with multiple mechanisms of action. [1, 2] It has also been found useful in conditions like migraine, bipolar and post-traumatic stress disorders, post-herpetic neuropathy and other neuralgic conditions as well. Acute myopia or acute angle-closure glaucoma is a serious rare side effect of the drug. This report documents one such case.
Case Report
A 40-year-old woman presented with the history of severe unilateral throbbing headaches associated with nausea and photo-and phono-phobia. The headache used to recur almost every fortnight and lasted for 2 to 3 days. She used to get relief, sometimes, with sleep and consumption of non-steroidal anti-inflammatory drugs. She had history of bronchial asthma. Her mother also used to experience similar headaches. She was obese BW (90 Kg) and was being treated with dietary restrictions, regular exercises, and a night dose of 10 mg of sibutramine. Neurological examination was essentially normal. Considering the clinical picture, diagnosis of migraine was entertained. She was put on flunarazine 5 mg and topiramate 25 mg before bedtime. Four days later, she complained of sudden loss of vision in both the eyes. On fundoscopy the discs were not well visual-Attorneys who represents victims of errors in medical management, mistakes in pharmaceutical manufacturing and medical malpractice, even suggested seeking legal opinion free of cost for such dangerous side effects.
[8] Jansen Ortho Inc. as well has issued their new prescribing information based on post-marketing experience in more than 8,25,000 patients and has stressed the occurrence of acute angle-closure glaucoma in the pediatric age group also. [9] Naranjo et al [10] devised a 10-item protocol to evaluate whether a drug could be considered responsible as the cause of an adverse reaction in a patient. For the lack of technical reasons and ethical considerations many items in the protocol could not be adhered to but it is worth following up the issue in collaboration with neuropharmacologists to establish incontrovertibly, the relevance of topiramate in the causation of such serious ocular problems. Thus it is important for the clinicians to educate the patients about this serious adverse event while prescribing topiramate and to advise them to report immediately in the event of visual obscuration. Prompt recognition of the complication and immediate stopping of the drug along with diuretic therapy is associated with the reversal of the symptoms.
